The market for Porokeratosis Treatment is anticipated to increase at a CAGR of 7% between 2024 and 2032. Numerous factors, such as an increase in renal transplant cases, enhanced reimbursement policies in developed nations, a rise in research funding, and intensifying competition among market participants, continue to contribute to the expansion of the global market. The porokeratosis treatment market is driven by multiple factors, including the increasing prevalence of the condition among healthcare professionals and patients. The rising incidence of porokeratosis is a significant factor driving the market for treatments for this condition. Porokeratosis is a rare disorder, but its incidence has increased in recent years due to factors such as increased exposure to UV radiation and increased use of immunosuppressive drugs.
The growing awareness of porokeratosis among healthcare professionals and patients, resulting in an increasing demand for effective treatments for the condition, is also driving the porokeratosis treatments market. As more people are diagnosed with porokeratosis, the need for information and education about the condition and its treatment increases. As a result, there is an increased demand for treatments and therapies that can help manage the symptoms of porokeratosis and improve the quality of life for those affected by the condition. Additionally, technological advancements in dermatology are driving the market growth. Additionally, the development of new, more effective therapies and treatments for porokeratosis drives demand these items. This includes the development of new topical and systemic therapies, as well as the introduction of new technologies such as photodynamic therapy and laser therapy. Increasing healthcare costs are a market driver as well. Patients are more willing to invest in porokeratosis treatment due to increased awareness of the condition and the availability of new treatments. This is causing an increase in the number of patients seeking treatment for porokeratosis, as well as an increase in healthcare costs.
Porokeratosis is an uncommon skin disorder that affects fewer than two hundred thousand Americans. The distribution of actinic porokeratosis is the most prevalent form of porokeratosis (DSAP). Prevalence estimates range from 23% to 61.1%, while incidence estimates range from 12.6% to 43.4% annually. DSAP is the most commonly treated disorder in the United States due to its high prevalence and incidence rates. Mibelli Porokeratosis is the second most common type of porokeratosis. Porokeratosis is a precancerous lesion that has the potential to develop into a malignant growth. Pokerokeratosis evolved into non-melanoma skin cancer in 6.9% to 30% of reported cases. According to one study, approximately 8% of those affected by Mibelli's porokeratosis develop skin cancer. In a single series, 10.68% of kidney transplant patients in Spain with a median age of 3.5 years developed porokeratosis.
Browse for report : https://www.acutemarketreports.com/report/porokeratosis-treatment-market
As the incidence of porokeratosis in renal transplant recipients rises, the market will be strengthened. According to a report, 10.68% of renal transplant recipients in the United States suffered from porokeratosis in 2017. DSAP is a form of porokeratosis caused by excessive sun exposure that primarily affects the forearms and legs. DSAP is diagnosed in nearly 43.4% of women between the ages of 30 and 50, which is twice as prevalent in women as it is in men. In cases where DSAP is harmful, there is a risk of developing squamous cell carcinomas at the affected site of the body.
There are numerous anti-infection creams and gels, thus expanding the market for treatment adoption. It is a rare disease that affects approximately 200,000 Americans. According to a publication from the National Library of Medicine, Diclofenac 3% gel is a potential treatment for DSAP, thus expanding its use.
The aesthetic appearance, performance, and elimination of malformed lesions were enhanced by the provided treatment. The treatment for porokeratosis is highly dependent on variables such as the size and location of the wound, the patient's aesthetic preferences, the availability of treatment, and the wound's appearance. The demand for porokeratosis treatment has increased due to an increase in disposable income and a deeper understanding of aesthetics. As a result, consumers view porokeratosis treatment as an essential component of a healthier lifestyle. The topical products are in high demand because they are readily available and simple to apply. Laser therapy is popular among affluent consumers despite its high cost. It does not require an incision or hospitalization, which contributes to its popularity and makes it a more popular treatment for porokeratosis.
In developed nations where disposable income and reimbursement regulations are increasing, consumers are increasingly concerned with aesthetics. Consumers in developed countries are becoming aware of the malignant transformation of the disease. The porokeratosis market will expand as the demand for personal care rises. There is adequate clinical surveillance to comprehend the malignant transformation of porokeratosis. This understanding has increased the demand for porokeratosis treatments. However, the majority of awareness is currently in developed nations, but the improved global dissemination of knowledge is rapidly expanding the market and awareness in developing nations.
Mild erythema, hyperpigmentation, and contemporary edoema are among the side effects of laser treatment. According to dermentz.org, no treatment has demonstrated long-term efficacy, which increases patients' reluctance to receive treatment. In addition, the high cost of treatment and people's lack of knowledge about skin treatments are additional obstacles to the development of porokeratosis treatment.
Laser therapy will be the market with the fastest growth during the forecast period of 2024 to 2032. Laser therapy has become an increasingly common treatment for porokeratosis. Using a laser, the physician destroys the area of the skin, allowing new skin to grow in its place. According to an article by Amarateedha Prak LeCourt, patients who underwent laser therapy for various types of porokeratosis experienced favorable outcomes. One patient with linear porokeratosis, for instance, showed improvement following the administration of 585 nm flashlamp-pumped pulsed dye laser. Another DSAP patient responded favorably to laser therapy. As laser therapy is risk-free and has no associated downtime or morbidity with pigment or textural changes, its adoption may contribute to the growth of porokeratosis treatment.
Hospitals will remain the market's largest end-user segment by the end of the forecast period of 2031. Hospitals represent a substantial market opportunity for the treatment of porokeratosis. Hospitals are prominent centers for the diagnosis and treatment of porokeratosis, and they offer an extensive range of services, including diagnostic testing, medical and surgical treatment, and follow-up care. This can result in increased opportunities for hospitals to generate revenue. Utilizing the most recent technologies and innovations in the treatment of porokeratosis, hospitals can improve patient outcomes and attract more patients. Hospitals are therefore well positioned to capitalize on the growing demand for effective porokeratosis treatments.
North America continues to be the global leader, as took the dominant position in 2023. The growth of the porokeratosis treatment market in North America is influenced by factors such as the rising prevalence of the condition, the increasing awareness among healthcare professionals and patients, and the availability of novel treatments and therapies. North America is expected to dominate the market due to the increasing prevalence of DSAP and the number of renal transplants. The incidence of porokeratosis has increased in tandem with the number of kidney transplant patients, according to sciencedirect.com.
According to niddk.nih.gov, more than 661,000 Americans have kidney failure and more than 468,000 patients are on dialysis. This may have an impact on porokeratosis cases, as 10% of patients with kidney problems have the condition. The expansion of healthcare infrastructure and expenditures influences Asia's contribution to the growth of the market. In addition, Japan's aging population has contributed to an increase in the number of cases of the disease. In Asia, the most prevalent types of porokerarosis are DSAP and Mibelli.
The increase in cases is due to a lack of knowledge about the treatment; therefore, the government should help people in rural areas gain knowledge about the treatment, which could lead to an increase in treatment adoption. Europe is in second place in the porokeratosis market due to rising incidences and innovations by researchers and manufacturers, which are driving the market growth. Increasing manufacturer involvement in the treatment of porokeratosis may stimulate market expansion.
The manufacturers of porokeratosis treatments employ a variety of expansion strategies to increase their share of the global protein market. According to the growing funding for the treatment of porokeratosis, key players are actively investing in more effective and superior porokeratosis treatments. Key players are investing in the development and introduction of a superior and cost-effective product for the porokeratosis treatment market, especially in developing nations with relatively low aesthetic spending. As a result of an increase in funding for porokeratosis treatment and the subsequent rise in product launches, competition among the major players is intense. Key market players include Coherent Inc., Alma Lasers, Almirall, Allergan, Pfizer, Lumenis, Coty Inc., Cutera, Bioness Inc., Biogen, PhotoMedex Inc., Valeant Pharmaceuticals, Hologic Inc., IPG Photonics Corporation, IRIDEX Corp. and others.
In December 2020, the FDA approved tirbanibulin, a new topical treatment for actinic keratosis developed by Almirall. The novel microtubule Tirbanibulin must be administered once every five days. In one of the largest Phase III clinical trials for Actinic Keratosis lesions, tirbanibulin demonstrated efficacy on the face and scalp of a large number of patients in 57 days. Hologic, a global leader in women's health, announced the acquisition of Biotheranostics, Inc. in January 2021. This organization offers molecular diagnostic tests for breast and metastatic cancers and is in the commercialization phase. The acquisition aims to leverage commercial capabilities, accelerate growth, offer more individualized treatment, and improve clinical outcomes for women.
